We therefore propose that CRELD2 is a potential druggable target in osteoclast precursors which could modulate osteoclast differentiation and osteolysis in diseases characterised by defective osteoclast differentiation and/or function such as osteopetrosis and osteoporosis. This evidence concerns the gene CRELD2 and osteopetrosis.